Retina I
Theme:
Retina
When:
3:15 PM, Saturday 26 Jun 2021
(1 hour 30 minutes)
Learning Objectives
At the end of this session, participants will be able to:
- Describe new therapeutic options for the treatment of neovascular macular degeneration
- Integrate key aspects of the evaluation of posterior uveitis
- Optimize management of submacular hemorrhage
CanMEDS Roles: Medical Expert, Scholar
Sub Sessions
Treatment switch from aflibercept to ranibizumab in Canadian DME patients in a real-world setting: the PRECISE study 237
3:35 PM
(8 minutes)
Part of:
Retina I
Speaker
Michel Giunta MD
Paper Presentation | Présentation d'article
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): 1-Year results from Phase 3 YOSEMITE and RHINE Trials
3:43 PM
(8 minutes)
Part of:
Retina I
Paper Presentation | Présentation d'article
Faricimab in Neovascular Age-Related Macular Degeneration: One-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
3:51 PM
(8 minutes)
Part of:
Retina I
Speaker
Dr. Raman Tuli
Paper Presentation | Présentation d'article
Sealing the Upper Edge of Mask Decreases Bacteria Dispersion to the Eyes of Mask Wearers
3:59 PM
(8 minutes)
Part of:
Retina I
Speaker
Shaobo Lei MD
Paper Presentation | Présentation d'article
Efficacy of intravitreal aflibercept (IVT-AFL) administered using a treat-and-extend (T&E) regimen in patients with macular edema secondary to central retinal vein occlusion (CRVO): The CENTERA study results
4:07 PM
(8 minutes)
Part of:
Retina I
Speaker
Varun Chaudhary
Paper Presentation | Présentation d'article
Posterior Uveitis: What you can't afford to miss in your clinic!
4:15 PM
(7 minutes)
Part of:
Retina I
Speaker
Dr. Nupura Bakshi
Talk | Exposé